UCB Plans 2000 Job Cuts

Aug. 28—Belgian drug maker UCB has announced plans to cut 2000 jobs worldwide in an effort to speed the company’s transition to a specialty drug company. The patents on two of UCB’s largest drugs are expiring, and the company is hoping the layoffs will enable them to direct $444 million into CNS and immunology research. Bloomberg 

Click here to log in.


Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

If You’re Moving to the Cloud, Who Are You Bringing with You?
Sponsored by Exostar

Privacy Analytics
De-Identification 101
Sponsored by Privacy Analytics

Life Science Webcasts & Podcasts

medidata_podcast_Sites and Sponsors: Mending Bridges over Troubled Waters  
Sites and Sponsors: Mending Bridges over Troubled Waters
Sponsored by Medidata Solutions Worldwide

This podcast brings together two industry leaders to focus on the issues that divide sponsors and sites. On the one hand sites and sponsors unite in advancing better health care through a common passion for developing better drugs. Yet some issues divide them and bridges need to be built or mended to advance the highest levels of cooperation, coordination and success in clinical trials. Listen as the key issues are debated from the site and the sponsor side and new methods and technology are advanced that offer near-term and lasting solutions.

• Common ground in reaching agreement on a budget

• Improving the pace of agreement on budgets and contracts

• Processes for payment to sites on a timely basis

Listen Now  

More Podcasts

Job Openings

For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.